Literature DB >> 20208136

Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse.

Maria Valeria Corrias1, Claudio Gambini, Andrea Gregorio, Michela Croce, Gaia Barisione, Claudia Cossu, Armando Rossello, Silvano Ferrini, Marina Fabbi.   

Abstract

BACKGROUND: The Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166), involved in nervous system development, has been linked to tumor progression and metastasis in several tumors. No information is available on ALCAM expression in neuroblastoma, a childhood neoplasia originating from the sympathetic nervous system.
METHODS: ALCAM expression was analysed by immunofluorescence and immunohistochemistry on differentiated neuroblastoma cell lines and on archival specimens of stroma-poor, not MYCN amplified, resectable neuroblastoma tumors, respectively.
RESULTS: ALCAM is variously expressed in neuroblastoma cell lines, is shed by metalloproteases and is cleaved by ADAM17/TACE in vitro. ALCAM is expressed in neuroblastoma primary tumors with diverse patterns of subcellular localization and is highly expressed in the neuropil area in a subgroup of cases. Tumor specimens showing high expression of ALCAM at the membrane of the neuroblast body or low levels in the neuropil area are associated with relapse (P=0.044 and P<0.0001, respectively). In vitro differentiated neuroblastoma cells show strong ALCAM expression on neurites, suggesting that ALCAM expression in the neuropil is related to a differentiated phenotype.
CONCLUSION: Assessment of ALCAM localization by immunohistochemistry may help to identify patients who, in the absence of negative prognostic factors, are at risk of relapse and require a more careful follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208136      PMCID: PMC4619103          DOI: 10.3233/CLO-2009-0494

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  6 in total

1.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Authors:  Fabio Morandi; Maria Valeria Corrias; Isabella Levreri; Paola Scaruffi; Lizzia Raffaghello; Barbara Carlini; Paola Bocca; Ignazia Prigione; Sara Stigliani; Loredana Amoroso; Soldano Ferrone; Vito Pistoia
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

2.  ALCAM: Basis Sequence: Mouse.

Authors:  Amanda G Hansen; Guido W Swart; Andries Zijlstra
Journal:  AFCS Nat Mol Pages       Date:  2011

3.  Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.

Authors:  Maike Ihnen; Kerstin Kress; Jan Felix Kersten; Ergin Kilic; Matthias Choschzick; Hilke Zander; Volkmar Müller; Sven Mahner; Fritz Jänicke; Linn Woelber; Karin Milde-Langosch
Journal:  BMC Cancer       Date:  2012-04-04       Impact factor: 4.430

4.  Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.

Authors:  Francesca Miccichè; Luca Da Riva; Marina Fabbi; Silvana Pilotti; Piera Mondellini; Silvano Ferrini; Silvana Canevari; Marco A Pierotti; Italia Bongarzone
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

Review 5.  Cell Adhesion Molecules and Ubiquitination-Functions and Significance.

Authors:  Mirka Homrich; Ingo Gotthard; Hilke Wobst; Simone Diestel
Journal:  Biology (Basel)       Date:  2015-12-23

6.  Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis.

Authors:  Katie E Hebron; Elizabeth Y Li; Shanna A Arnold Egloff; Ariana K von Lersner; Chase Taylor; Joep Houkes; David K Flaherty; Adel Eskaros; Thomas P Stricker; Andries Zijlstra
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.